PENZBERG, Germany–Roche Applied Science announced the start of the Roche Prime Supply Program today. Prime Supply is an on-site stocking program ensuring immediate availability of Roche Applied Science products. This system provides efficient and economical access to consignment stock stored on site at your facility, avoiding supply and delivery issues and reducing delays in your research. The user obtains the reagents he/she needs at a moment’s notice, relying on a user-friendly computerized interface, improved cost savings, and an uninterrupted supply of trusted Roche research products

The users benefit from the fact that they have an extensive product selection within walking distance of their lab. The system comes with customized real-time inventory with automatic stock adjustments. For each account as well as for individual users, security, reporting and tracking tools are provided.

Electronic access to program and inventory is very easy. With a personalized user ID, the user chooses the products from stock or from the Roche Applied Science catalog. The user can add the products to the shopping cart and modify the quantity as needed. After opening the freezer, the Pick-to-Light System quickly leads the way to the desired product within the cabinets and drawers.

For more information, visit www.roche-applied-science.com

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at www.roche.com.